Literature DB >> 10580179

Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?

F J Nieto1, C Iribarren, M D Gross, G W Comstock, R G Cutler.   

Abstract

BACKGROUND: the evidence of a potential beneficial role of antioxidants in preventing atherosclerotic disease is not entirely consistent.
OBJECTIVE: to assess the longitudinal association of serum total antioxidant capacity and serum antioxidants with the presence of subclinical carotid atherosclerosis.
METHODS: Prospective case-control study nested within an historical cohort. Cases were 150 individuals with elevated carotid intimal-medial thickness measured by B-mode ultrasound at the first two examinations of the Atherosclerosis Risk in Communities Study (1987-92). Controls were 150 age-gender-matched individuals with low carotid intimal-medial thickness. Serum antioxidant vitamins, uric acid, and serum total antioxidant capacity were measured in frozen serum samples collected from the same individuals in 1974 (13-15 years prior to the determination of case-control status).
RESULTS: Compared to controls, atherosclerosis cases had significantly higher levels of serum total antioxidant capacity in 1974 than controls. This difference was almost entirely explained by increased serum concentration of uric acid in cases. In contrast with cross-sectional results, uric acid serum concentration in 1974, was significantly higher in cases than in controls, even after adjusting for the main cardiovascular risk factors. Cases had significantly lower levels of alpha-carotene in the 1974 sera than controls, but no other differences in serum antioxidant vitamin concentrations were observed.
CONCLUSIONS: The higher serum uric acid concentration seemed associated with elevated total serum antioxidant capacity among individuals with atherosclerosis. This finding is consistent with experimental evidence suggesting that hyperuricemia may be a compensatory mechanism to counteract oxidative damage related to atherosclerosis and aging in humans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10580179     DOI: 10.1016/s0021-9150(99)00214-2

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  104 in total

1.  Effect of serum insulin on the association between hyperuricemia and incident heart failure.

Authors:  Ravi V Desai; Mustafa I Ahmed; Gregg C Fonarow; Gerasimos S Filippatos; Michel White; Inmaculada B Aban; Wilbert S Aronow; Ali Ahmed
Journal:  Am J Cardiol       Date:  2010-10-15       Impact factor: 2.778

2.  Serum uric acid and cardiovascular disease.

Authors:  Adriana Iliesiu; Alexandru Campeanu; Dinu Dusceac
Journal:  Maedica (Buchar)       Date:  2010-07

3.  Uric acid: a danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome, and cardiorenal disease: evolutionary considerations.

Authors:  Richard J Johnson; Miguel A Lanaspa; Eric A Gaucher
Journal:  Semin Nephrol       Date:  2011-09       Impact factor: 5.299

4.  Reactions of peroxynitrite with uric acid: formation of reactive intermediates, alkylated products and triuret, and in vivo production of triuret under conditions of oxidative stress.

Authors:  Christine Gersch; Sergiu P Palii; Witcha Imaram; Kyung Mee Kim; S Ananth Karumanchi; Alexander Angerhofer; Richard J Johnson; George N Henderson
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2009-02       Impact factor: 1.381

5.  Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients.

Authors:  Ryuji Chida; Itaru Hisauchi; Shigeru Toyoda; Migaku Kikuchi; Takaaki Komatsu; Yuichi Hori; Shiro Nakahara; Yoshihiko Sakai; Teruo Inoue; Isao Taguchi
Journal:  Hypertens Res       Date:  2015-07-16       Impact factor: 3.872

Review 6.  Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal?

Authors:  Zohreh Soltani; Kashaf Rasheed; Daniel R Kapusta; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

7.  The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease.

Authors:  Peter Higgins; Jesse Dawson; Matthew Walters
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-11-04

Review 8.  Fructose and cardiometabolic disorders: the controversy will, and must, continue.

Authors:  Nicolas Wiernsperger; Alain Geloen; Jean-Robert Rapin
Journal:  Clinics (Sao Paulo)       Date:  2010-07       Impact factor: 2.365

9.  Is elevated SUA associated with a worse outcome in young Chinese patients with acute cerebral ischemic stroke?

Authors:  Bin Zhang; Cong Gao; Ning Yang; WeiZhi Zhang; XingWang Song; JianRui Yin; ShuXiang Pu; YongHong Yi; QingChun Gao
Journal:  BMC Neurol       Date:  2010-09-18       Impact factor: 2.474

10.  Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia.

Authors:  N C den Hollander; D J Mulder; R Graaff; S R Thorpe; J W Baynes; G P A Smit; A J Smit
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.